Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ years of age.~* Moderate to severe rheumatoid arthritis of ≥ 6 months duration.~* Receiving treatment on an outpatient basis.~* Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68 joint count) at screening and study start.~* On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.~* Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.~* Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.~* Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.~* Prior history of or current inflammatory joint disease other than rheumatoid arthritis.~* History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations.~Other inclusion and exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 162 mg sc (Type: EXPERIMENTAL): Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
- Placebo sc (Type: PLACEBO_COMPARATOR): Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).